← Back to Clinical Trials
Recruiting NCT05715203

NCT05715203 Aortic Stiffness in Patients With Genetic Aortopathies

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05715203
Status Recruiting
Phase
Sponsor IRCCS Policlinico S. Donato
Condition Rare Diseases
Study Type OBSERVATIONAL
Enrollment 250 participants
Start Date 2023-02-15
Primary Completion 2025-11-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Pulsotonometry

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 250 participants in total. It began in 2023-02-15 with a primary completion date of 2025-11-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to study arterial stiffness in patients with thoracic ascending aortic aneurysms (TAA), either syndromic or non-syndromic. The main questions it aims to answer are: * Stratification of aortic risk based on arterial stiffness; Compare measurements with morphological and haemodynamic features of the ascending thoracic aorta. Participants will be asked to undergo non-invasive evaluation of blood pressure and arterial stiffness.

Eligibility Criteria

Inclusion Criteria: * Subjects with AAT, either syndromic or non syndromic; * Signed informed consent Exclusion Criteria: * Patients with early menopause and/or osteoporosis, rheumatic heart disease and active malignant tumours; * Patients with acute and chronic inflammatory conditions such as: chronic liver disease, chronic renal insufficiency and diseases affecting the thyroid system; * Seropositivity to HIV, HCV, HBsAg and SARS-CoV-2; * Pregnancy

Contact & Investigator

Central Contact

Alessandro Pini, MD

✉ alessandro.pini@grupposandonato.it

📞 +390252774705

Principal Investigator

Alessandro Pini

PRINCIPAL INVESTIGATOR

Cardiovascular-Gentic Centre, IRCCS Policlinico San Donato

Frequently Asked Questions

Who can join the NCT05715203 clinical trial?

This trial is open to participants of all sexes, studying Rare Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05715203 currently recruiting?

Yes, NCT05715203 is actively recruiting participants. Contact the research team at alessandro.pini@grupposandonato.it for enrollment information.

Where is the NCT05715203 trial being conducted?

This trial is being conducted at San Donato Milanese, Italy.

Who is sponsoring the NCT05715203 clinical trial?

NCT05715203 is sponsored by IRCCS Policlinico S. Donato. The principal investigator is Alessandro Pini at Cardiovascular-Gentic Centre, IRCCS Policlinico San Donato. The trial plans to enroll 250 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology